1-7 of 7
Noriaki Sawada
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT565: Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer

Shuichi Mitsunaga, Masafumi Ikeda, Kazunori Aoki, Kyoko Yamaguchi, Noriaki Sawada, Etsuko Fujii, Masanobu Nishidate, Takashi Fujitomo, Hideaki Mizuno, Yoko Kayukawa, Atsuhiko Kato, Mayu Makikawa, Hiroshi Imaoka, Mitsuhito Sasaki, Kazuo Watanabe, Hiroyuki Tsunoda, Kimio Terao, Atsushi Ochiai
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT565.
https://doi.org/10.1158/1538-7445.AM2022-CT565
Published: 15 June 2022
View articletitled, Abstract CT565: Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
Journal Articles

Abstract 6145: Increased PD-L1 expression levels were observed on both tumor cells and macrophages by tocilizumab plus gemcitabine/nab-paclitaxel treatment in gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer patients

Kyoko Yamaguchi, Etsuko Fujii, Shuichi Mitsunaga, Noriaki Sawada, Masafumi Ikeda, Takashi Fujitomo, Hideaki Mizuno, Yoko Kayukawa, Mayu Makikawa, Kazunori Aoki, Hiroshi Imaoka, Mitsuhito Sasaki, Kazuo Watanabe, Atsukiko Kato, Hiroyuki Tsunoda, Kimio Terao, Atsushi Ochiai
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 6145.
https://doi.org/10.1158/1538-7445.AM2022-6145
Published: 15 June 2022
View articletitled, Abstract 6145: Increased PD-L1 expression levels were observed on both tumor cells and macrophages by tocilizumab plus gemcitabine/nab-paclitaxel treatment in gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer patients
Journal Articles

Abstract 1886: Anti -GPRC5D/CD3 T cell-redirecting bispecific antibody with potent in vitro and in vivo antitumor efficacy against multiple myeloma

Tatsushi Kodama, Yu Kochi, Waka Nakai, Hideaki Mizuno, Takeshi Baba, Kiyoshi Habu, Noriaki Sawada, Hiroyuki Tsunoda, Takahiro Shima, Kohta Miyawaki, Yoshikane Kikushige, Yasuo Mori, Toshihiro Miyamoto, Takahiro Maeda, Koichi Akashi
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1886.
https://doi.org/10.1158/1538-7445.AM2021-1886
Published: 01 July 2021
View articletitled, Abstract 1886: Anti -GPRC5D/CD3 T cell-redirecting bispecific antibody with potent in vitro and in vivo antitumor efficacy against multiple myeloma
Journal Articles

Abstract 2378: Differential exhaustion on cytokine release (DECREASE) by ERY974, a novel T-cell-redirecting antibody targeting glypican-3: A new type of T-cell exhaustion

Mayumi Hoshino, Yuji Sano, Yasuko Kinoshita, Yumiko Azuma, Toshiaki Tsunenari, Yoko Kayukawa, Mizuho Noguchi, Takahiro Ishiguro, Shohei Kishishita, Noriaki Sawada, Mika Endo, Junichi Nezu
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2378.
https://doi.org/10.1158/1538-7445.AM2019-2378
Published: 01 July 2019
View articletitled, Abstract 2378: Differential exhaustion on cytokine release (DECREASE) by ERY974, a novel T-cell-redirecting antibody targeting glypican-3: A new type of T-cell exhaustion
Journal Articles

Functional anti-cell proliferative antibodies obtained from NOG-established tumor lines

Juliana Sim, Yu Jau Chen, Sharon Sng, Shinta Kobayashi, Takeshi Watanabe, Noriaki Sawada, Yasayuki Ohnishi, Junichi Nezu, Koichi Matsubara
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 1475.
Published: 01 May 2007
View articletitled, Functional anti-cell proliferative antibodies obtained from NOG-established tumor lines
Journal Articles

Identification of CDCP1 as a novel molecular target of anti-cancer therapeutic antibody targeting prostate cancer

Jun-ichi Nezu, Shinta Kobayashi, Eri Hashimoto, Noriaki Sawada, Masakazu Hasegawa, Yuko Aoki, Kunihiro Hattori
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 638.
Published: 01 May 2007
View articletitled, Identification of CDCP1 as a novel molecular target of anti-cancer therapeutic antibody targeting prostate cancer
Journal Articles

Positive Correlation between the Efficacy of Capecitabine and Doxifluridine and the Ratio of Thymidine Phosphorylase to Dihydropyrimidine Dehydrogenase Activities in Tumors in Human Cancer Xenografts

Tohru Ishikawa, Fumiko Sekiguchi, Yu Fukase, Noriaki Sawada, Hideo Ishitsuka
Journal: Cancer Research
Cancer Res (1998) 58 (4): 685–690.
Published: 01 February 1998
View articletitled, Positive Correlation between the Efficacy of Capecitabine and Doxifluridine and the Ratio of Thymidine Phosphorylase to Dihydropyrimidine Dehydrogenase Activities in Tumors in Human Cancer Xenografts
Open the PDF for Positive Correlation between the Efficacy of Capecitabine and Doxifluridine and the Ratio of Thymidine Phosphorylase to Dihydropyrimidine Dehydrogenase Activities in Tumors in Human Cancer Xenografts in another window